US · won_by_plaintiff · ~8 min read
Dr. Miles Medical Co. v. John D. Park & Sons (1911)
1908–1911 · patent medicines, wholesale distribution
A drug company tried to control what pharmacies charged for its medicines. The Supreme Court said manufacturers cannot agree with stores to set minimum prices—that was automatic illegal price fixing until Leegin changed the rule in 2007.
The story
Dr. Miles sold proprietary medicines through distributors bound by agency contracts requiring set retail prices—common today as MAP policies, revolutionary then legally.
When wholesaler John D. Park sold below required prices, Dr. Miles sued to enforce the contract terms.
The Supreme Court rejected the strategy: vertical agreements fixing minimum resale prices were per se unreasonable restraints of trade, even if the manufacturer held patents.
The opinion drew a bright line—horizontal price fixing among competitors is illegal; vertical price maintenance got the same per se treatment, unlike other vertical restraints judged case-by-case.
For ninety-six years Dr. Miles blocked most minimum RPM programs unless hidden in subtler policies.
Economists later argued the rule harmed interbrand competition and consumer service; Leegin finally abandoned per se treatment in 2007.
Reading Dr. Miles today shows how antitrust doctrine swings between bright-line bans and economic rule-of-reason analysis.
Why it matters
Historical foundation for vertical price restraint law.
Explains why Leegin was a seismic shift.
Distribution contracts still cite Dr. Miles history in briefing.
What was claimed
Vertical minimum price contracts restrain trade per se.
Patent rights do not authorize price fixing downstream.
Dr. Miles could not enforce fixed retail prices.
The other side
Dr. Miles argued agency status avoided restraint characterization.
Later commentators said the economics were underdeveloped.
What it means for you
Modern MAP policies exist in Leegin's shadow, not Dr. Miles's ban.
Historical cases shape today's dealer termination disputes.
Bottom line
Dr. Miles created America's century-long automatic ban on minimum resale price maintenance—until Leegin retired it.
Timeline
1900s
Patent medicine distribution
Dr. Miles used agency contracts to control retail pricing of remedies.
1911
Per se vertical RPM ban
Court separated vertical price restraints from patent rights to fix prices.
Key dates
- Distribution dispute arises
- 1908
- Supreme Court decision
- January 3, 1911
- Rule overturned by Leegin
- 2007
Formal snapshot
Summary: The Supreme Court held vertical agreements fixing minimum resale prices were per se illegal under the Sherman Act—establishing the rule Leegin later overturned in 2007.
Regulator / plaintiff argument: Dr. Miles's agency contracts fixing retail prices for proprietary medicines unlawfully restrained trade by controlling downstream prices.
Outcome: 1911 per se ban on vertical minimum RPM; dominated US law for nearly a century.
Remedies: N/A—doctrinal precedent.
Conduct tags
Laws referenced
- Sherman Act §1 — 15 U.S.C. §1
Companies
Reader signals
0 reads · synced via local demo storage — add NEXT_PUBLIC_SUPABASE_* to enable shared likes and comments
Comments
No comments yet — start the thread.